Argenta has signed a subcontracting agreement with Pulmagen Therapeutics to perform integrated services on two respiratory projects.
Argenta will be eligible to receive as much as $10 million in fee-for-service payments over two years, with the possibility of extensions, to perform chemistry, biology, ADMET/PK and pharmacology services to bring two respiratory projects to preclinical status.
"We are pleased that Pulmagen has come to Argenta for two projects of such substantial scope. These projects will make a strong contribution to the service operations' performance in 2011," said Dr. Chris Newton, senior vice president Services of Galapagos. "This agreement also demonstrates how well positioned Argenta is to perform longer term, integrated projects for its clients."
The deal with Argenta is part of a discovery and development collaboration that Pulmagen established with Chiesi Farmaceutici, a private Italian group, with focus in respiratory diseases.
The purpose of the discovery programs is to identify new compounds with anti-inflammatory potential to be developed for respiratory conditions characterized by a high unmet medical need such as COPD and cystic fibrosis.
The terms of the collaboration between Pulmagen and Chiesi are not disclosed.